Remove

Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number			
iling Date		2006-08-09	
First Named Inventor Jante		e Kromkamp	
Art Unit		_	
Examiner Name			
Attorney Docket Number		101137-72	

Examiner Cite Initial* No		Patent Number Kind Code <sup>1</sup>		Issue Date		Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date		Name of Pat of cited Docu	entee or Applicant ument	Releva	Columns,Lines when ant Passages or Relev s Appear	
	1	20030132175	A1	2003-07	7-17	Kiderman et a	al.	Entire	document	
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information	please click the Ad	d button	Add	
				FOREIG	SN PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	70
	1	0 588 348	EP		A2	1994-03-23	Nihon Millipore Ko Kabushiko Kaisha	gyo	Entire document Document cited in International Search Report (copy attached), document not provided	
	2	0 595 689	EP		A1	1994-05-04	Commissariat A L'Energie Atomiqu		Entire document. Document cited in International Search Report (copy attached), document not provided	Г
	3	1 020 180	NL.		С	2003-09-16	Aquamarijn Holdin te Hengelo	g B.V.	Entire document Document cited in International Search Report (copy attached), document not provided:	

U.S.PATENTS

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-08-09
First Named Inventor Jantje		e Kromkamp
Art Unit		
Examiner Name		
Attorney Docket Number		101137-72

			NON-P	ATENT LIT	ERATURE DO	CUMENTS	Remove	Τ
If you wis	h to a	dd additional Fore	ign Patent Docur	ment citation	n information p	lease click the Add butto		
	7	01/10540	wo	A2	2001-02-15	Microfiltration Technology APS	Entire document. Document cited in International Search Report (copy attached), document not provided	
	6	102 24 513	DE	A1	2003-12-11	Tuchenhagen GmbH	Entire document.  Document cited in International Search Report (copy attached), document not provided	
	5	1 043 053	EP	A1	2000-10-11	Vlaamse Instelling Voor Technologisch Onderzoek	Entire document. Document cited in International Search Report (copy attached), document not provided	
	4	2 586 202	FR	A1	1987-02-20	Centre Meridional D'Cenologie	Entire document. Document cited in International Search Report (copy attached), document not provided	

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

publisher, city and/or country where published.

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST 3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Initials\* No

Examiner Signature

# Application Number Flang Date 2006-08-09 Flank The Temperature The Temperature

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

See attached certification statement.

Fee set forth in 37 CFR 1,17 (p) has been submitted herewith.

7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/bruce s londa/	Date (YYYY-MM-DD)	2006-08-09
Name/Print	Bruce S. Londa	Registration Number	33531

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol file and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenar's Office, and Compartment of Commence, P. 0. Bast 1436, Alexandria, V.32.311.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.311.450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.